The Company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide ...

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has ...

Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the ...

Eli Lilly's Mounjaro, a new diabetes and weight loss drug, is making waves in India. Approved by the drug regulator, this weekly injection shows promise but comes with high costs and potential ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

“Mounjaro (tirzepatide) is the first-in-class dual GLP-1 and GIP receptor agonist, offering a groundbreaking approach to weight loss and diabetes management. Originally developed for type 2 ...

Alembic Pharmaceuticals and Amlan International, the animal health business of Oil-Dri Corporation of America, have entered into a strategic commercial agreement to introduce poultry health ...

Opens in a new tab or window Last week marked the FDA's deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some patients unsure where to turn next.

Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

A new study shows that long-term use of tirzepatide in people with type 1 diabetes and overweight or obesity resulted in significant weight loss as well as marked improvements in A1C, time in range, ...

For the unversed, Mounjaro, chemically known as tirzepatide, is primarily used for controlling blood sugar levels in individuals with type-2 diabetes. Just like Novo Nordisk's Ozempic, it also ...

Jessica Baylis, 44, of Greenlawn, who has lost nearly 40 pounds since she began taking compounded tirzepatide in 2023, said she would have difficulty paying name-brand prices. Zepbound and ...